ประเภทหลักทรัพย์ : หุ้นสามัญ | วันที่มีผลใช้บังคับ : 06/10/2566 | วันที่ปิดการขาย : 11/10/2566
Type of securities : Common share | Effective Date : 06/10/2023 | Close Selling Date : 11/10/2023
March 2018 increased by 19% yoy mainly from the surge of provisions for employee benefit and other liabilities. Most of the increase of other liabilities was income tax payable on 2017 profit because
% 51.41 63.64% 4. Livestock 11.47 3.62% 9.27 2.50% (2.20) (19.18%) Total Sales revenues 316.83 100.00% 371.33 100.00% 54.50 17.20% Such growth was driven by a surge in revenues from sales of companion
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
www.interpharma.co.th Inter Pharma Co. Ltd. 140/9 ITF Tower, 9th Floor, Silom Road, Suriyawong, Bangrak, Bangkok 10500, Thailand. Tel. 02-634-0225 Fax 02-634-0135 www.interpharma.co.th a surge in revenues from sales of
YoY. Transfer ownership of condominium unit of the ESSE at Singha Complex, the ESSE Asoke and Banyan Tree Residences Riverside Bangkok mainly attributed to the surge. Residential projects for sales as
% YoY. Transfer ownership of condominium unit of the ESSE at Singha Complex since September 2019, the ESSE Asoke and Banyan Tree Residences Riverside Bangkok mainly attributed to the surge. Residential
, inventories and property, plant and equipment. Cash received from the initial public offering (IPO) and cash from operations contributed to the surge in total assets. Total Liabilities As of 30 June 2018, the
shareholders’ equity of THB 4,973.36 million. The surge in shareholders’ equity was mainly caused by the Company’s initial public offering (IPO) as well as the retained earnings from the Company’s performance